Vericiguat is one of the routine medications given to patients with heart failure and reduced ejection fraction. However, the effect, efficacy, and safety of the vericiguat are not well studied. The objective of this study is to evaluate the efficacy and safety of vericiguat in patients with heart failure and reduced ejection fraction.
This randomized, double-blinded, placebo-controlled, phase-3 trial included a total of 5,050 patients with chronic heart (class 2, 3, or 4) and an ejection fraction less than 45%. The patients were randomized in a 1:1 ratio to receive vericiguat (10mg daily, n=2,526) or placebo (n=2,524). The primary endpoint of the study was a composite of death from cardiovascular causes. First hospitalization cases for heart failure were also considered.
During the mean follow-up of 10.8 months, a composite of death due to cardiovascular occurred in 897 patients (35.5%) in the vericiguat group and 972 patients (38.5%) in the placebo group. In addition, the first hospitalization due to heart failure was reported in 691 patients (27.4%) in the vericiguat group and 441 patients (37.9%) in the placebo group. The incidence of adverse events was the same in the two groups.
The research concluded that in patients with chronic risk failure and reduced ejection fraction, vericiguat was associated with a reduced risk of death from cardiovascular causes or hospitalization for heart failure.